Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Apr;69(4):717–720. doi: 10.1038/bjc.1994.135

Prospective evaluation of cell kinetics in head and neck squamous carcinoma: the relationship to tumour factors and survival.

L D Cooke 1, T G Cooke 1, G Forster 1, A S Jones 1, P M Stell 1
PMCID: PMC1968830  PMID: 8142259

Abstract

Tumour growth rates were measured in 105 patients using in vivo incorporation of bromodeoxyuridine (BrdU) and investigated for any relationship to tumour factors or survival. The median labelling index (LI) was 8.7%, the duration of S-phase (Ts) was 14 h and the potential doubling time (Tpot) was 5.9 days. The labelling index in aneuploid tumours was significantly higher than that in diploid tumours. However the total labelling index (TLI) did not differ significantly between aneuploid and diploid tumours, and so it would seem likely that the difference in LI is due to the dilutional effect of benign tissue upon the calculation of LI in diploid tumours. The total labelling index, duration of S-phase and potential doubling time were not related to the tumour factors examined (site, T stage, N stage, stage grouping). Interim survival analysis was carried out and there was no difference in survival between those patients with high values for TLI, Ts, and Tpot and those with low values.

Full text

PDF
717

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Begg A. C., McNally N. J., Shrieve D. C., Kärcher H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry. 1985 Nov;6(6):620–626. doi: 10.1002/cyto.990060618. [DOI] [PubMed] [Google Scholar]
  2. Bennett M. H., Wilson G. D., Dische S., Saunders M. I., Martindale C. A., Robinson B. M., O'Halloran A. E., Leslie M. D., Laing J. H. Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck. Br J Cancer. 1992 Jun;65(6):870–878. doi: 10.1038/bjc.1992.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Conte P. F., Alama A., Rubagotti A., Chiara S., Nicolin A., Nicolò, Rosso R., Gaddi M., Ghiringhello B., Tomao S. Cell kinetics in ovarian cancer. Relationship to clinicopathologic features, responsiveness to chemotherapy, and survival. Cancer. 1989 Sep 15;64(6):1188–1191. doi: 10.1002/1097-0142(19890915)64:6<1188::aid-cncr2820640604>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  4. Cooke T. G., Stanton P. D., Winstanley J., Murray G. D., Croton R., Holt S., George W. D. Long-term prognostic significance of thymidine labelling index in primary breast cancer. Eur J Cancer. 1992;28(2-3):424–426. doi: 10.1016/s0959-8049(05)80067-x. [DOI] [PubMed] [Google Scholar]
  5. Ensley J. F., Maciorowski Z., Hassan M., Pietraszkiewicz H., Heilbrun L., Kish J. A., Tapazoglou E., Jacobs J. R., al-Sarraf M. Cellular DNA content parameters in untreated and recurrent squamous cell cancers of the head and neck. Cytometry. 1989 May;10(3):334–338. doi: 10.1002/cyto.990100313. [DOI] [PubMed] [Google Scholar]
  6. Forster G., Cooke T. G., Cooke L. D., Stanton P. D., Bowie G., Stell P. M. Tumour growth rates in squamous carcinoma of the head and neck measured by in vivo bromodeoxyuridine incorporation and flow cytometry. Br J Cancer. 1992 May;65(5):698–702. doi: 10.1038/bjc.1992.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Franzén G., Klintenberg C., Olofsson J., Risberg B. DNA measurement--an objective predictor of response to irradiation? A review of 24 squamous cell carcinomas of the oral cavity. Br J Cancer. 1986 May;53(5):643–651. doi: 10.1038/bjc.1986.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Greenberg B., Woo L., Blatchford S., Aguirre M., Garewal H. Variability of the thymidine labeling index in squamous cell carcinoma of the head and neck. Laryngoscope. 1988 Jun;98(6 Pt 1):668–670. doi: 10.1288/00005537-198806000-00018. [DOI] [PubMed] [Google Scholar]
  9. Hemmer J. In vitro bromodeoxyuridine labelling of squamous cell carcinomas of the oral cavity. Eur J Cancer. 1990 Feb;26(2):113–115. doi: 10.1016/0277-5379(90)90292-2. [DOI] [PubMed] [Google Scholar]
  10. Hirano T., Zitsch R. P., 3rd, Gluckman J. L. The use of bromodeoxyuridine cytokinetic studies as a prognostic indicator of cancer of the head and neck. Laryngoscope. 1991 Feb;101(2):130–133. doi: 10.1288/00005537-199102000-00005. [DOI] [PubMed] [Google Scholar]
  11. Johnson T. S., Williamson K. D., Cramer M. M., Peters L. J. Flow cytometric analysis of head and neck carcinoma DNA index and S-fraction from paraffin-embedded sections: comparison with malignancy grading. Cytometry. 1985 Sep;6(5):461–470. doi: 10.1002/cyto.990060511. [DOI] [PubMed] [Google Scholar]
  12. Kinsella T. J., Russo A., Mitchell J. B., Rowland J., Jenkins J., Schwade J., Myers C. E., Collins J. M., Speyer J., Kornblith P. A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation. Int J Radiat Oncol Biol Phys. 1984 Jan;10(1):69–76. doi: 10.1016/0360-3016(84)90414-0. [DOI] [PubMed] [Google Scholar]
  13. Mitchell J. B., Kinsella T. J., Russo A., McPherson S., Rowland J., Smith B. H., Kornblith P. L., Glatstein E. Radiosensitization of hematopoietic precursor cells (CFUc) in glioblastoma patients receiving intermittent intravenous infusions of bromodeoxyuridine (BUdR). Int J Radiat Oncol Biol Phys. 1983 Apr;9(4):457–463. doi: 10.1016/0360-3016(83)90061-5. [DOI] [PubMed] [Google Scholar]
  14. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976 Dec;34(6):585–612. doi: 10.1038/bjc.1976.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rew D. A., Wilson G. D., Taylor I., Weaver P. C. Proliferation characteristics of human colorectal carcinomas measured in vivo. Br J Surg. 1991 Jan;78(1):60–66. doi: 10.1002/bjs.1800780120. [DOI] [PubMed] [Google Scholar]
  16. Riccardi A., Danova M., Wilson G., Ucci G., Dörmer P., Mazzini G., Brugnatelli S., Girino M., McNally N. J., Ascari E. Cell kinetics in human malignancies studied with in vivo administration of bromodeoxyuridine and flow cytometry. Cancer Res. 1988 Nov 1;48(21):6238–6245. [PubMed] [Google Scholar]
  17. Silvestrini R., Molinari R., Costa A., Volterrani F., Gardani G. Short-term variation in labeling index as a predictor of radiotherapy response in human oral cavity carcinoma. Int J Radiat Oncol Biol Phys. 1984 Jul;10(7):965–970. doi: 10.1016/0360-3016(84)90164-0. [DOI] [PubMed] [Google Scholar]
  18. Tubiana M., Courdi A. Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival. Radiother Oncol. 1989 May;15(1):1–18. doi: 10.1016/0167-8140(89)90113-8. [DOI] [PubMed] [Google Scholar]
  19. Wilson G. D. Assessment of human tumour proliferation using bromodeoxyuridine--current status. Acta Oncol. 1991;30(8):903–910. doi: 10.3109/02841869109088242. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES